Alhakak A, Butt JH, Fosbøl EL, et al. - Using data from Danish nationwide registries, researchers herein investigated the risk of adverse outcomes across the spectrum of glycated hemoglobin(HbA1c) levels among COVID-19 patients with and without diabetes.

• A total of 3,295 hospitalized COVID-19 patients with an available HbA1c were identified (56.2% males and median age 73.9 years); 35.8% of these had diabetes.

• Per findings, patients with COVID-19 and HbA1c < 48 mmol/mol or HbA1c > 64 mmol/mol appeared to be at higher risk of all-cause mortality and the composite of severe COVID-19 infection, intensive care unit(ICU)admission, or all-cause mortality.

• Similarly, among patients without diabetes, higher risk of the composite outcome was observed in correlation with varying HbA1c levels.